CAMP4 clears Australian hurdle for first human CMP-002 study in SYNGAP1 disorder
CAMP4 gains Australian clearance for a Phase 1/2 CMP-002 trial targeting the genetic cause of SYNGAP1-related disorder.
Pharma & Biotech
CAMP4 gains Australian clearance for a Phase 1/2 CMP-002 trial targeting the genetic cause of SYNGAP1-related disorder.